This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
CFR Pharmaceuticals: Potential Synergies in Africa
Charlene C. LewCase IVEY-9B14C049-ELeadership and People Management, StrategyThe third-generation leader of CFR Pharmaceuticals had been successful in executing a strategy of consolidating pharmaceutical firms across Latin America. As part of the company’s expansion strategy, the CEO explored opportunities to develop multiple sources of growth and expand CFR Pharmaceutical’s footprint in emerging markets; to do this, he found a company in South Africa, Adcock Ingram, to acquire. The combined company would offer CFR produc...Starting at €8.20
-
Adcock Ingram: Decisions and Motives That Steer Acquisitions
Charlene C. LewCase IVEY-9B10C008-ELeadership and People Management, StrategyThe case sketches the story of a charismatic and ambitious young business leader who, through value-adding commercial transactions, has helped set a South African pharmaceutical company, Adcock Ingram, on a trajectory of growth. In May 2009, he faces lack of closure and an ambiguous outcome to an offer to acquire a smaller pharmaceutical company. The case demonstrates the power of relationships, where the ambitions of different parties around the...Starting at €8.20
-
The Awethu Project: Values-Driven Decisions for Profit and Social Impact
Charlene C. LewCase IVEY-9B17C018-EEntrepreneurship, Leadership and People Management, StrategyThe Awethu Project (Awethu) was a South African-based social enterprise that operated as a venture capital and investment firm for small, medium, and micro-sized enterprises. The company was widely acknowledged for its social mission of creating jobs and benefiting society while maximizing profit. In March 2016, Awethu’s leaders signed an agreement with a prominent South African corporation, which could allow Awethu to operate within a higher seg...Starting at €8.20